Céleste J T van der Togt

Publication Activity (10 Years)

Years Active: 2022-2023
Publications (10 Years): 7

Top Topics

Randomized Controlled Trial

Coronavirus Disease

Top Venues

Therapeutic advances in musculoskeletal disease

Rheumatology (Oxford, England)

This page only lists publications with an associated author ORCID identifier.

Publications

Céleste J T van der Togt, Bart Van den Bemt, Daniel Aletaha, Rieke E Alten, Katerina Chatzidionysiou, James B Galloway, John Isaac, Denis Mulleman, Patrick Verschueren, Arnold G Vulto, Paco M J Welsing, Lise Verhoef, Alfons A den Broeder
Points to consider for cost-effective use of biological and targeted synthetic DMARDs in inflammatory rheumatic diseases: results from an umbrella review and international Delphi study. RMD open 9 (1) (2023)
Céleste J T van der Togt, Bart Van den Bemt, Daniel Aletaha, Rieke E Alten, Katerina Chatzidionysiou, James B Galloway, John Isaac, Denis Mulleman, Patrick Verschueren, Arnold G Vulto, Paco M J Welsing, Lise Verhoef, Alfons A den Broeder
Points to consider for cost-effective use of biological and targeted synthetic DMARDs in inflammatory rheumatic diseases: results from an umbrella review and international Delphi study. RMD open 9 (1) (2023)
Céleste J T van der Togt, Bart Van den Bemt, Daniel Aletaha, Rieke E Alten, Katerina Chatzidionysiou, James B Galloway, John Isaac, Denis Mulleman, Patrick Verschueren, Arnold G Vulto, Paco M J Welsing, Lise Verhoef, Alfons A den Broeder
Points to consider for cost-effective use of biological and targeted synthetic DMARDs in inflammatory rheumatic diseases: results from an umbrella review and international Delphi study. RMD open 9 (1) (2023)
Céleste J T van der Togt, Bart Van den Bemt, Daniel Aletaha, Rieke E Alten, Katerina Chatzidionysiou, James B Galloway, John Isaac, Denis Mulleman, Patrick Verschueren, Arnold G Vulto, Paco M J Welsing, Lise Verhoef, Alfons A den Broeder
Points to consider for cost-effective use of biological and targeted synthetic DMARDs in inflammatory rheumatic diseases: results from an umbrella review and international Delphi study. RMD open 9 (1) (2023)
Céleste J T van der Togt, David F Ten Cate, Nathan den Broeder, Janette Rahamat-Langendoen, Bart J F van den Bemt, Alfons A den Broeder
Humoral response to coronavirus disease-19 vaccines is dependent on dosage and timing of rituximab in patients with rheumatoid arthritis. Rheumatology (Oxford, England) 61 (SI2) (2022)
Céleste J T van der Togt, Lise M Verhoef, Bart J F van den Bemt, Nathan den Broeder, Rob Ter Heine, Alfons A den Broeder
Pharmacokinetic boosting to enable a once-daily reduced dose of tofacitinib in patients with rheumatoid arthritis and psoriatic arthritis (the PRACTICAL study). Therapeutic advances in musculoskeletal disease 14 (2022)
Céleste J T van der Togt, Lise M Verhoef, Bart J F van den Bemt, Nathan den Broeder, Rob Ter Heine, Alfons A den Broeder
Pharmacokinetic boosting to enable a once-daily reduced dose of tofacitinib in patients with rheumatoid arthritis and psoriatic arthritis (the PRACTICAL study). Therapeutic advances in musculoskeletal disease 14 (2022)